2021. Dec. 27

This is the news of the investment attraction of OneCureGen, the 1000th research institute company that SWP participated in the establishment with ICure, a KOSDAQ-listed company.

On the 20th, OneCureGen Co., Ltd. announced that it has attracted Series A investment in a year and a half since its foundation.

PassFinderH, Korea Investment Partners, Sema Investment, IBK Capital-Harang Technology Holdings, and Venture Capital Town participated in the investment.

In this investment, OneCureGen was recognized for its corporate value of about 24 billion won. OneCureGen is a bio-venture established in July last year by combining the Korea Biotechnology Research Institute's technology to discover drug targets and develop peptide treatments and iCureBNP's drug delivery technology. In September last year, it was approved by the Ministry of Science and ICT as the 1,000th research institute company.

OneCuregen has pipelines such as treatments for newly identified anti-cancer targets VGLL1 and SYT11 using cancer treatment target discovery technology and HIF-1 target low-molecular anti-cancer drug candidates widely known for winning the Nobel Prize in Physiology or Medicine.

OneCureGen said, "We will use this investment to build platform technology for developing peptide anticancer drugs and to conduct non-clinical trials." 

Related press release : 

▶ MoneyToday : https://news.mt.co.kr/mtview.php?no=2021122011284212041

▶ eDaily : https://www.edaily.co.kr/news/read?newsId=02233686629280488&mediaCodeNo=257&OutLnkChk=Y 

▶ HanKyung : https://www.hankyung.com/it/article/202112200123i